Document is current

Article History

First Online: 30 January 2020

Compliance with Ethical Standards

:

: AbbVie Inc.

: <i>E. Louis</i> has received consulting and/or lecture fees from AbbVie, Ferring, MSD, Falk, Takeda, Hospira, Janssen, Pfizer, and Celgene; research grants from Takeda and Pfizer; and educational grants from AbbVie, Takeda, and Janssen; and has served on advisory boards for AbbVie, Ferring, MSD, Takeda, Celgene, Hospira, and Janssen. <i>J.M. Ramos</i>-<i>Goñi</i> has received consulting fees from AbbVie for conducting this research work. However, J.M. Ramos-Goñi does not have any conflict of interest with the results of this research. <i>J. Cuervo</i> has received consulting fees from AbbVie for conducting this research work. However, J. Cuervo does not have any conflict of interest with respect to the results of this research. <i>U. Kopylov</i> has received research grants from Janssen, Takeda, and Medtronic; speaker fees from Janssen, AbbVie, Takeda, MSD, and CTS; and advisory fees from Janssen, AbbVie, and Takeda. <i>M. Barreiro</i>-<i>de Acosta</i> has received financial support from AbbVie for this research. <i>S. McCartney</i> has received consulting, lecturing, or advisory board fees from AbbVie, Ferring, MSD, Falk, Takeda, and Janssen. <i>A. Hart</i> has served as consultant, advisory board member, or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda. She also serves on the Global Steering Committee for Genentech. <i>G. Rosenfeld</i> has received financial support for research projects and speaking engagements, and consulting fees from several pharmaceutical companies. This support was not anticipated to impact this study. He also received support to enable him to attend the in-person meeting that formed a part of this study. <i>K. Novak</i> has received honoraria from AbbVie for participating in this research. <i>D. Easton</i> and <i>E. Tzur</i> have participated in AbbVie-sponsored research. <i>R. Saldaña</i> has not received any benefit from participating in this study. However, the patient association for which he works has received honoraria from AbbVie. <i>D. Bettenworth</i> is on the advisory board or has been a consultant for AbbVie, Amgen, Falk Foundation, Ferring, MSD, Pharmacosmos, Pfizer, Roche, Takeda, Tillotts Pharma, and Vifor. <i>X. Donnet</i> has received support for travel to meetings for this research study from AbbVie Inc. The non-profit patient association “Association Crohn-RCUH”, for which X. Donnet volunteers (as a Crohn patient), is sponsored by AbbVie, Dr Falk, Ferring, Janssen, Janssens, Pfizer, Takeda, and UCB. <i>K. Protze</i> has received consulting fees from AbbVie for participating in this research. However, K. Protze does not have any conflict of interest with respect to the results of this research. <i>F. Casellas</i> has received research funding from AbbVie, MSD, Shire, Ferring, and Zambon and speaker fees from AbbVie, MSD, Shire, Ferring, Zambon, Gebro, Chiesi, and Takeda. <i>G. Alperovich</i> is an AbbVie employee and may own AbbVie stock and/or options.

: The authors and AbbVie scientists designed the research and analysed and interpreted the data. AbbVie funded the research and provided writing support. All authors contributed to the development of the content. The authors and AbbVie reviewed and approved the manuscript; the authors maintained control over the final content.